These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1207 related articles for article (PubMed ID: 33654292)

  • 1. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
    Wibmer CK; Ayres F; Hermanus T; Madzivhandila M; Kgagudi P; Oosthuysen B; Lambson BE; de Oliveira T; Vermeulen M; van der Berg K; Rossouw T; Boswell M; Ueckermann V; Meiring S; von Gottberg A; Cohen C; Morris L; Bhiman JN; Moore PL
    Nat Med; 2021 Apr; 27(4):622-625. PubMed ID: 33654292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
    Wibmer CK; Ayres F; Hermanus T; Madzivhandila M; Kgagudi P; Oosthuysen B; Lambson BE; de Oliveira T; Vermeulen M; van der Berg K; Rossouw T; Boswell M; Ueckermann V; Meiring S; von Gottberg A; Cohen C; Morris L; Bhiman JN; Moore PL
    bioRxiv; 2021 Mar; ():. PubMed ID: 33501446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
    Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A
    Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
    Moyo-Gwete T; Madzivhandila M; Makhado Z; Ayres F; Mhlanga D; Oosthuysen B; Lambson BE; Kgagudi P; Tegally H; Iranzadeh A; Doolabh D; Tyers L; Chinhoyi LR; Mennen M; Skelem S; Marais G; Wibmer CK; Bhiman JN; Ueckermann V; Rossouw T; Boswell M; de Oliveira T; Williamson C; Burgers WA; Ntusi N; Morris L; Moore PL
    N Engl J Med; 2021 Jun; 384(22):2161-2163. PubMed ID: 33826816
    [No Abstract]   [Full Text] [Related]  

  • 5. Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2.
    Saade C; Gonzalez C; Bal A; Valette M; Saker K; Lina B; Josset L; Trabaud MA; Thiery G; Botelho-Nevers E; Paul S; Verhoeven P; Bourlet T; Pillet S; Morfin F; Trouillet-Assant S; Pozzetto B; On Behalf Of Covid-Ser Study Group
    Emerg Microbes Infect; 2021 Dec; 10(1):1499-1502. PubMed ID: 34176436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
    Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
    Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.
    Li Q; Nie J; Wu J; Zhang L; Ding R; Wang H; Zhang Y; Li T; Liu S; Zhang M; Zhao C; Liu H; Nie L; Qin H; Wang M; Lu Q; Li X; Liu J; Liang H; Shi Y; Shen Y; Xie L; Zhang L; Qu X; Xu W; Huang W; Wang Y
    Cell; 2021 Apr; 184(9):2362-2371.e9. PubMed ID: 33735608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
    Jia Z; Gong W
    J Korean Med Sci; 2021 May; 36(18):e124. PubMed ID: 33975397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The great escape? SARS-CoV-2 variants evading neutralizing responses.
    Prévost J; Finzi A
    Cell Host Microbe; 2021 Mar; 29(3):322-324. PubMed ID: 33705702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape.
    Rani PR; Imran M; Lakshmi JV; Jolly B; Jain A; Surekha A; Senthivel V; Chandrasekhar P; Divakar MK; Srinivasulu D; Bhoyar RC; Vanaja PR; Scaria V; Sivasubbu S
    J Med Virol; 2021 Jul; 93(7):4163-4165. PubMed ID: 33818797
    [No Abstract]   [Full Text] [Related]  

  • 13. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
    Muik A; Wallisch AK; Sänger B; Swanson KA; Mühl J; Chen W; Cai H; Maurus D; Sarkar R; Türeci Ö; Dormitzer PR; Şahin U
    Science; 2021 Mar; 371(6534):1152-1153. PubMed ID: 33514629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.
    Li R; Ma X; Deng J; Chen Q; Liu W; Peng Z; Qiao Y; Lin Y; He X; Zhang H
    Cell Mol Immunol; 2021 Apr; 18(4):1058-1060. PubMed ID: 33580167
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.
    Jamieson TR; Poutou J; Marius R; He X; Rezaei R; Azad T; Ilkow CS
    J Vis Exp; 2021 Jun; (172):. PubMed ID: 34152313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system.
    de Queiroz NMGP; Marinho FV; Chagas MA; Leite LCC; Homan EJ; de Magalhães MTQ; Oliveira SC
    Microbes Infect; 2020; 22(10):515-524. PubMed ID: 32961274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
    Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
    Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 61.